Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone

R A Star, N Rajora, J Huang, R C Stock, A Catania, J M Lipton, R A Star, N Rajora, J Huang, R C Stock, A Catania, J M Lipton

Abstract

alpha-Melanocyte-stimulating hormone (alpha-MSH) is a potent inhibitory agent in all major forms of inflammation. To identify a potential mechanism of antiinflammatory action of alpha-MSH, we tested its effects on production of nitric oxide (NO), believed to be a mediator common to all forms of inflammation. We measured NO and alpha-MSH production in RAW 264.7 cultured murine macrophages stimulated with bacterial lipopolysaccharide and interferon gamma. alpha-MSH inhibited production of NO, as estimated from nitrite production and nitration of endogenous macrophage proteins. This occurred through inhibition of production of NO synthase II protein; steady-state NO synthase II mRNA abundance was also reduced. alpha-MSH increased cAMP accumulation in RAW cells, characteristic of alpha-MSH receptors in other cell types. RAW cells also expressed mRNA for the primary alpha-MSH receptor (melanocortin 1). mRNA for proopiomelanocortin, the precursor molecular of alpha-MSH, was expressed in RAW cells, and tumor necrosis factor alpha increased production and release of alpha-MSH. These results suggest that the proinflammatory cytokine tumor necrosis factor alpha can induce macrophages to increase production of alpha-MSH, which then becomes available to act upon melanocortin receptors on the same cells. Such stimulation of melanocortin receptors could modulate inflammation by inhibiting the production of NO. The results suggest that alpha-MSH is an autocrine factor in macrophages which modulates inflammation by counteracting the effects of proinflammatory cytokines.

References

    1. Fed Proc. 1985 Jan;44(1 Pt 1):112-7
    1. J Biol Chem. 1951 Nov;193(1):265-75
    1. Anal Biochem. 1974 Apr;58(2):541-8
    1. J Immunol. 1977 Sep;119(3):950-54
    1. Cell. 1978 Sep;15(1):261-7
    1. J Biol Chem. 1983 Jan 10;258(1):257-61
    1. Anal Biochem. 1982 Oct;126(1):131-8
    1. Anal Biochem. 1987 Apr;162(1):156-9
    1. Endocrinology. 1987 Nov;121(5):1900-7
    1. J Invest Dermatol. 1989 Oct;93(4):511-7
    1. Peptides. 1990 Sep-Oct;11(5):979-82
    1. Br J Pharmacol. 1990 Dec;101(4):815-20
    1. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6368-71
    1. Lancet. 1991 Dec 21-28;338(8782-8783):1555-7
    1. J Biol Chem. 1992 Mar 25;267(9):6370-4
    1. Ann Intern Med. 1992 Sep 1;117(5):408-14
    1. Cytokine. 1992 Jul;4(4):320-8
    1. FEBS Lett. 1992 Sep 14;309(3):417-20
    1. Science. 1992 Aug 28;257(5074):1248-51
    1. Acta Physiol Scand. 1992 Jul;145(3):201-27
    1. J Clin Invest. 1992 Nov;90(5):1718-25
    1. J Clin Invest. 1993 Feb;91(2):730-4
    1. J Biol Chem. 1993 Apr 15;268(11):8246-50
    1. Ann N Y Acad Sci. 1993 May 31;680:412-23
    1. J Biol Chem. 1993 Jul 15;268(20):15174-9
    1. Kidney Int. 1993 Jul;44(1):43-9
    1. J Leukoc Biol. 1993 Aug;54(2):171-8
    1. Biochem Biophys Res Commun. 1993 Sep 15;195(2):1134-8
    1. Brain Res Bull. 1993;32(3):311-4
    1. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8856-60
    1. N Engl J Med. 1993 Dec 30;329(27):2002-12
    1. Endocr Rev. 1993 Oct;14(5):564-76
    1. Neuroendocrinology. 1994 Feb;59(2):138-43
    1. Biochem J. 1994 Apr 15;299 ( Pt 2):367-73
    1. J Biol Chem. 1994 May 6;269(18):13162-6
    1. J Clin Invest. 1994 May;93(5):2258-62
    1. Genomics. 1994 Jan 15;19(2):394-5
    1. Biol Chem Hoppe Seyler. 1994 Feb;375(2):81-8
    1. Arthritis Rheum. 1994 Jul;37(7):1062-9
    1. J Clin Invest. 1994 Jul;94(1):328-36
    1. FEBS Lett. 1994 Aug 15;350(1):9-12
    1. Ann N Y Acad Sci. 1994 Nov 25;741:137-48
    1. Neuroimmunomodulation. 1994 Jan;1(1):28-32
    1. Neuroimmunomodulation. 1994 Mar-Apr;1(2):93-9
    1. Neuroimmunomodulation. 1994 Sep-Oct;1(5):321-8
    1. Science. 1974 Apr 5;184(4132):19-28

Source: PubMed

3
Prenumerera